1. Home
  2. REPL

as 05-30-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Founded: 2015 Country:
United States
United States
Employees: N/A City: WOBURN
Market Cap: 578.4M IPO Year: 2018
Target Price: $20.00 AVG Volume (30 days): 1.6M
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.07 EPS Growth: N/A
52 Week Low/High: $4.93 - $17.00 Next Earning Date: 05-22-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

REPL Daily Stock ML Predictions

Stock Insider Trading Activity of Replimune Group Inc. (REPL)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Patel Sushil REPL Chief Executive Officer May 20 '25 Sell $8.06 25,105 $202,346.30 343,576
Sarchi Christopher REPL Chief Commercial Officer May 20 '25 Sell $8.05 3,749 $30,179.45 128,296
Xynos Konstantinos REPL Chief Medical Officer May 20 '25 Sell $8.06 7,952 $64,093.12 146,933
Schwendenman Andrew REPL Chief Accounting Officer May 20 '25 Sell $8.05 3,287 $26,460.35 68,284
Hill Emily Luisa REPL Chief Financial Officer May 20 '25 Sell $8.05 2,535 $20,406.75 143,522

Share on Social Networks: